Abstract
Accumulating evidence implicates deficiencies in apolipoprotein D (ApoD) function and arachidonic acid signaling in schizophrenic disorders. We addressed two hypotheses in relation to ApoD: first, polymorphisms in the ApoD gene confer susceptibility to or are markers of disease, and, second, genetic variation in the ApoD is associated with long-term clinical outcome to antipsychotic treatment. We genotyped two single-nucleotide polymorphisms in the ApoD gene in 343 chronic patients with schizophrenia spectrum disorders (ICD-10) and 346 control subjects of Danish origin. We did not find ApoD alleles, genotypes or haplotypes to be associated with disease. However, we did find that long-term clinical outcome was associated with the ApoD polymorphism rs7659 (P = 0.041) following adjustment for lifetime clinical global impression, age at first admission and gender.
Original language | English |
---|---|
Pages (from-to) | 120-125 |
Number of pages | 6 |
Journal | Pharmacogenomics Journal |
Volume | 6 |
Issue number | 2 |
DOIs | |
Publication status | Published - 2006 |
Keywords
- adult
- antipsychotic agents
- apolipoproteins D
- case-control studies
- DNA
- female
- genetic predisposition ti disease
- humans
- logistic models
- male
- middle aged
- multivariate analysis
- polymorphism
- single nucleotide
- risk factors
- schizophrenia
- time factors
- treatment outcome
- chronic schizophrenia
- clozapine
- treatment refractory
- lipid metabolism
- neurodegeneration
- long-term outcome